PURPOSE: Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in BRCA1/2-mutant ovarian and breast cancers, RUCAPANC investigated the efficacy and safety of rucaparib in BRCA1/2-mutant pancreatic cancer. PATIENTS AND METHODS: RUCAPANC enrolled patients with measurable locally advanced/metastatic pancreatic cancer who had received one to two prior chemotherapy regimens. Patients received oral rucaparib (600 mg twice daily) until disease progression. The primary end point was objective response rate. RESULTS: Nineteen patients were enrolled. Sixteen of 19 BRCA1/2 mutations were germ-line; three were somatic. Patients had received a median of two prior chemotherapy regimens. Four patients achieved a response; two partial responses and one complete response (CR) were confirmed (objective response rate, 15.8%; 3 of 19), with an additional CR unconfirmed. The disease control rate (CR, partial response, or stable disease for ≥ 12 weeks) was 31.6% (6 of 19) in all patients and 44.4% (4 of 9) in those who had received one prior chemotherapy regimen. As prespecified in the protocol, enrollment was stopped because of an insufficient response rate among the first 15 patients. Treatment-emergent adverse events included nausea (63.2%) and anemia (47.4%). Grade ≥ 3 adverse events included anemia (31.6%), fatigue (15.8%), and ascites (15.8%). Secondary resistance mutations were detected in circulating free tumor DNA in two patients with a germline BRCA2 mutation. These mutations are predicted to lead to the reversion of a somatic-not germline-mutation. CONCLUSION: Rucaparib provided clinical benefit to patients with advanced pancreatic cancer and a BRCA1/2 mutation, and demonstrated an acceptable safety profile. Additional trials of rucaparib in this population are warranted.
PURPOSE: Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in BRCA1/2-mutant ovarian and breast cancers, RUCAPANC investigated the efficacy and safety of rucaparib in BRCA1/2-mutant pancreatic cancer. PATIENTS AND METHODS: RUCAPANC enrolled patients with measurable locally advanced/metastatic pancreatic cancer who had received one to two prior chemotherapy regimens. Patients received oral rucaparib (600 mg twice daily) until disease progression. The primary end point was objective response rate. RESULTS: Nineteen patients were enrolled. Sixteen of 19 BRCA1/2 mutations were germ-line; three were somatic. Patients had received a median of two prior chemotherapy regimens. Four patients achieved a response; two partial responses and one complete response (CR) were confirmed (objective response rate, 15.8%; 3 of 19), with an additional CR unconfirmed. The disease control rate (CR, partial response, or stable disease for ≥ 12 weeks) was 31.6% (6 of 19) in all patients and 44.4% (4 of 9) in those who had received one prior chemotherapy regimen. As prespecified in the protocol, enrollment was stopped because of an insufficient response rate among the first 15 patients. Treatment-emergent adverse events included nausea (63.2%) and anemia (47.4%). Grade ≥ 3 adverse events included anemia (31.6%), fatigue (15.8%), and ascites (15.8%). Secondary resistance mutations were detected in circulating free tumor DNA in two patients with a germline BRCA2 mutation. These mutations are predicted to lead to the reversion of a somatic-not germline-mutation. CONCLUSION: Rucaparib provided clinical benefit to patients with advanced pancreatic cancer and a BRCA1/2 mutation, and demonstrated an acceptable safety profile. Additional trials of rucaparib in this population are warranted.
Authors: Anosheh Afghahi; Kirsten M Timms; Shaveta Vinayak; Kristin C Jensen; Allison W Kurian; Robert W Carlson; Pei-Jen Chang; Elizabeth Schackmann; Anne-Renee Hartman; James M Ford; Melinda L Telli Journal: Clin Cancer Res Date: 2017-01-13 Impact factor: 12.531
Authors: Min Geun Lee; Sang Hyub Lee; Seung June Lee; Yoon Suk Lee; Jin-Hyeok Hwang; Ji Kon Ryu; Yong-Tae Kim; Dong Uk Kim; Sang Myung Woo Journal: Chemotherapy Date: 2014-01-18 Impact factor: 2.544
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Barbara Norquist; Kaitlyn A Wurz; Christopher C Pennil; Rochelle Garcia; Jenny Gross; Wataru Sakai; Beth Y Karlan; Toshiyasu Taniguchi; Elizabeth M Swisher Journal: J Clin Oncol Date: 2011-06-27 Impact factor: 44.544
Authors: Elizabeth M Swisher; Kevin K Lin; Amit M Oza; Clare L Scott; Heidi Giordano; James Sun; Gottfried E Konecny; Robert L Coleman; Anna V Tinker; David M O'Malley; Rebecca S Kristeleit; Ling Ma; Katherine M Bell-McGuinn; James D Brenton; Janiel M Cragun; Ana Oaknin; Isabelle Ray-Coquard; Maria I Harrell; Elaina Mann; Scott H Kaufmann; Anne Floquet; Alexandra Leary; Thomas C Harding; Sandra Goble; Lara Maloney; Jeff Isaacson; Andrew R Allen; Lindsey Rolfe; Roman Yelensky; Mitch Raponi; Iain A McNeish Journal: Lancet Oncol Date: 2016-11-29 Impact factor: 41.316
Authors: Britta Weigelt; Iñaki Comino-Méndez; Ino de Bruijn; Lei Tian; Jane L Meisel; Isaac García-Murillas; Charlotte Fribbens; Ros Cutts; Luciano G Martelotto; Charlotte K Y Ng; Raymond S Lim; Pier Selenica; Salvatore Piscuoglio; Carol Aghajanian; Larry Norton; Rajmohan Murali; David M Hyman; Laetitia Borsu; Maria E Arcila; Jason Konner; Jorge S Reis-Filho; Roger A Greenberg; Mark E Robson; Nicholas C Turner Journal: Clin Cancer Res Date: 2017-08-01 Impact factor: 12.531
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday Journal: Nature Date: 2005-04-14 Impact factor: 69.504
Authors: Kara N Maxwell; Bradley Wubbenhorst; Brandon M Wenz; Daniel De Sloover; John Pluta; Lyndsey Emery; Amanda Barrett; Adam A Kraya; Ioannis N Anastopoulos; Shun Yu; Yuchao Jiang; Hao Chen; Nancy R Zhang; Nicole Hackman; Kurt D'Andrea; Robert Daber; Jennifer J D Morrissette; Nandita Mitra; Michael Feldman; Susan M Domchek; Katherine L Nathanson Journal: Nat Commun Date: 2017-08-22 Impact factor: 14.919
Authors: Michael J Pishvaian; Edik M Blais; Jonathan R Brody; Emily Lyons; Patricia DeArbeloa; Andrew Hendifar; Sam Mikhail; Vincent Chung; Vaibhav Sahai; Davendra P S Sohal; Sara Bellakbira; Dzung Thach; Lola Rahib; Subha Madhavan; Lynn M Matrisian; Emanuel F Petricoin Journal: Lancet Oncol Date: 2020-03-02 Impact factor: 41.316
Authors: Ritu R Singh; Johanna Goldberg; Anna M Varghese; Kenneth H Yu; Wungki Park; Eileen M O'Reilly Journal: Cancer Treat Rev Date: 2019-03-22 Impact factor: 12.111
Authors: Wungki Park; Jiapeng Chen; Nadeem Riaz; Eileen M O'Reilly; Joanne F Chou; Anna M Varghese; Kenneth H Yu; Winston Wong; Marinela Capanu; Vinod Balachandran; Caitlin A McIntyre; Imane El Dika; Danny N Khalil; James J Harding; Nima Ghalehsari; Zoe McKinnell; Sree B Chalasani; Vladimir Makarov; Pier Selenica; Xin Pei; Nicolas Lecomte; David P Kelsen; Ghassan K Abou-Alfa; Mark E Robson; Liying Zhang; Michael F Berger; Nikolaus Schultz; Timothy A Chan; Simon N Powell; Jorge S Reis-Filho; Christine A Iacobuzio-Donahue Journal: Clin Cancer Res Date: 2020-05-22 Impact factor: 12.531
Authors: Andge Valiakhmetova; Sergey Gorelyshev; Alexander Konovalov; Yuri Trunin; Alexander Savateev; David E Kram; Eric Severson; Amanda Hemmerich; Claire Edgerly; Daniel Duncan; Nicholas Britt; Richard S P Huang; Julia Elvin; Vincent Miller; Jeffrey S Ross; Laurie Gay; Joshua McCorkle; Andrew Rankin; Rachel L Erlich; Yakov Chudnovsky; Shakti H Ramkissoon Journal: Oncologist Date: 2019-10-16
Authors: Christine Alewine; Mehwish Ahmad; Cody J Peer; Zishuo I Hu; Min-Jung Lee; Akira Yuno; Jessica D Kindrick; Anish Thomas; Seth M Steinberg; Jane B Trepel; William D Figg; Raffit Hassan; Ira Pastan Journal: Clin Cancer Res Date: 2019-12-02 Impact factor: 12.531
Authors: Samantha A Armstrong; Christopher W Schultz; Ariana Azimi-Sadjadi; Jonathan R Brody; Michael J Pishvaian Journal: Mol Cancer Ther Date: 2019-11 Impact factor: 6.261